These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

239 related items for PubMed ID: 39168500

  • 1. Comparative oral monotherapy of psilocybin, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, ayahuasca, and escitalopram for depressive symptoms: systematic review and Bayesian network meta-analysis.
    Hsu TW, Tsai CK, Kao YC, Thompson T, Carvalho AF, Yang FC, Tseng PT, Hsu CW, Yu CL, Tu YK, Liang CS.
    BMJ; 2024 Aug 21; 386():e078607. PubMed ID: 39168500
    [Abstract] [Full Text] [Related]

  • 2. Psychedelic-assisted therapy for treating anxiety, depression, and existential distress in people with life-threatening diseases.
    Schipper S, Nigam K, Schmid Y, Piechotta V, Ljuslin M, Beaussant Y, Schwarzer G, Boehlke C.
    Cochrane Database Syst Rev; 2024 Sep 12; 9(9):CD015383. PubMed ID: 39260823
    [Abstract] [Full Text] [Related]

  • 3. Psychedelics and Psychedelic-Assisted Psychotherapy.
    Reiff CM, Richman EE, Nemeroff CB, Carpenter LL, Widge AS, Rodriguez CI, Kalin NH, McDonald WM, the Work Group on Biomarkers and Novel Treatments, a Division of the American Psychiatric Association Council of ResearchDepartment of Psychiatry, New York University School of Medicine, New York (Reiff); Department of Psychiatry and Human Behavior, Emory University School of Medicine, Atlanta (Richman, McDonald); Department of Psychiatry, Dell Medical School and the Institute for Early Life Adversity Research, University of Texas at Austin (Nemeroff); Department of Psychiatry and Human Behavior, Butler Hospital, Brown University, Providence, R.I. (Carpenter); Department of Psychiatry and Behavioral Sciences, University of Minnesota, Minneapolis (Widge); Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, Calif., and Veterans Affairs Palo Alto Health Care System, Palo Alto, Calif. (Rodriguez); Department of Psychiatry, University of Wisconsin School of Medicine and Public Health, Madison (Kalin)..
    Am J Psychiatry; 2020 May 01; 177(5):391-410. PubMed ID: 32098487
    [Abstract] [Full Text] [Related]

  • 4. Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review.
    Breeksema JJ, Kuin BW, Kamphuis J, van den Brink W, Vermetten E, Schoevers RA.
    J Psychopharmacol; 2022 Oct 01; 36(10):1100-1117. PubMed ID: 36017784
    [Abstract] [Full Text] [Related]

  • 5. Post-acute psychological effects of classical serotonergic psychedelics: a systematic review and meta-analysis.
    Goldberg SB, Shechet B, Nicholas CR, Ng CW, Deole G, Chen Z, Raison CL.
    Psychol Med; 2020 Dec 01; 50(16):2655-2666. PubMed ID: 33143790
    [Abstract] [Full Text] [Related]

  • 6. Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews.
    Dos Santos RG, Bouso JC, Alcázar-Córcoles MÁ, Hallak JEC.
    Expert Rev Clin Pharmacol; 2018 Sep 01; 11(9):889-902. PubMed ID: 30102078
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Efficacy of psychedelics in psychiatry, a systematic review of the literature].
    Berkovitch L, Roméo B, Karila L, Gaillard R, Benyamina A.
    Encephale; 2021 Aug 01; 47(4):376-387. PubMed ID: 33888297
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis.
    Metaxa AM, Clarke M.
    BMJ; 2024 May 01; 385():e078084. PubMed ID: 38692686
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The association between study design and antidepressant effects in psychedelic-assisted therapy: A meta-analysis.
    Li JR, Chiang KT, Kao YC, Yu CL, Yang FC, Liang CS, Hsu TW.
    J Affect Disord; 2025 Jan 15; 369():421-428. PubMed ID: 39389119
    [Abstract] [Full Text] [Related]

  • 15. A Critical Appraisal of Evidence on the Efficacy and Safety of Serotonergic Psychedelic Drugs as Emerging Antidepressants: Mind the Evidence Gap.
    Ledwos N, Rosenblat JD, Blumberger DM, Castle DJ, McIntyre RS, Mulsant BH, Husain MI.
    J Clin Psychopharmacol; 2025 Jan 15; 42(6):581-588. PubMed ID: 36193898
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Assessing the risk-benefit profile of classical psychedelics: a clinical review of second-wave psychedelic research.
    Bender D, Hellerstein DJ.
    Psychopharmacology (Berl); 2022 Jun 15; 239(6):1907-1932. PubMed ID: 35022823
    [Abstract] [Full Text] [Related]

  • 18. Psychedelics for Patients With Cancer: A Comprehensive Literature Review.
    White CM, Weisman N, Dalo J.
    Ann Pharmacother; 2023 Sep 15; 57(9):1062-1075. PubMed ID: 36635883
    [Abstract] [Full Text] [Related]

  • 19. Trial of Psilocybin versus Escitalopram for Depression.
    Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, Martell J, Blemings A, Erritzoe D, Nutt DJ.
    N Engl J Med; 2021 Apr 15; 384(15):1402-1411. PubMed ID: 33852780
    [Abstract] [Full Text] [Related]

  • 20. Psychedelics for treatment resistant depression: are they game changers?
    Kalfas M, Taylor RH, Tsapekos D, Young AH.
    Expert Opin Pharmacother; 2023 Apr 15; 24(18):2117-2132. PubMed ID: 37947195
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.